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Background. HIV-positive people starting combined antiretroviral therapy may develop immune reconstitution to latent or
treated opportunistic infections. Immune reconstitution to cerebral Cryptococcus is poorly understood and can be fatal. Case
Presentation. A 33-year-old Zimbabwean female presented with cryptococcal meningitis and newly diagnosed HIV with a CD4
count of 51 cells/𝜇L (4%). She was treated with amphotericin and flucytosine. Combined antiretroviral therapy was started
four weeks later and she showed early improvement. However, over the ensuing 18 months, her clinical course was marked
by periodic worsening with symptoms resembling cryptococcal meningitis despite having achieved CD4 counts ≥400 cells/𝜇L.
Although initially treated for relapsing cryptococcal immune reconstitution syndrome, a brain biopsy taken 17 months after initial
presentation showed budding Cryptococci. Conclusion.This unusually protracted case highlights the difficulties in differentiating
relapsing cryptococcal meningitis from immune reconstitution and raises questions concerning the optimum timing of initiation
of combined antiretroviral therapy in such patients.
1. Introduction
We describe a patient with cryptococcal meningitis and
an atypical immune reconstitution syndrome (IRIS) with
multiple relapses over 18 months. We explore the diagnostic
and therapeutic challenges surrounding the recognition and
management of such relapsing cryptococcal disease. We also
elaborate on how this rare case provided further insight into
the pathological progression of IRIS, a phenomenon still not
fully understood.
2. Case
In July 2005, a 33 year old Zimbabwean female, resident in
the UK for 8 years, was admitted with a week history of fever,
headache, and neck stiffness. She had no past medical history
of note. Systemic examination showed fever and meningism
but no focal neurological deficits. Blood tests revealed mild
anaemia, lymphopenia, and raised C-reactive protein. An
HIV test was positive with CD4 count of 51 cells/𝜇L (4%). CT
head without contrast showed marked meningeal inflamma-
tion but no focal lesions. A lumbar puncture (LP) revealed
raised opening pressure (OP) of 27 cmsH
2
0, lymphocyte
count (30/cumm), protein (1.33 g/L), andCSF: serum glucose
ratio of 50%. Cerebral spinal fluid (CSF) microscopy showed
multiple yeast with high cryptococcal antigen (CRAG) titre
of>1 : 25,600. CSFAcid-alcohol fast bacilli (AAFB), toxoplas-
mosis, and viral screenswere negative.Thepatientwas started
on standard amphotericin with flucytosine and prophylactic
cotrimoxazole.
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On day five of therapy, she began to complain of increas-
ing headache and neck stiffness. A right-sided sixth nerve
palsy was noted as a new neurological sign. An MRI brain
showed changes in keeping with chronic meningitis and
occipitoparietal changes (Figure 1(a)). Repeat LP revealedOP
of 40 cmsH
2
0 with persistently high protein and lymphocyte
count. Over the next twoweeks, the patient required a lumbar
drain to alleviate excruciating pressure-related headaches.
CSF cultures revealed Cryptococcus neoformans sensi-
tive to amphotericin B (Minimum Inhibitory Concentration
“MIC” 0.125mg/L) and itraconazole (MIC 0.03mg/L) and
intermediate to fluconazole (MIC 4.0mg/L) and flucytosine
(MIC 8.0mgL). Amphotericin and flucytosine were contin-
ued for four weeks and then switched to oral fluconazole
800mg once daily. This prolonged initial phase was based
on symptom severity, high fungal burden, and relatively high
MIC to fluconazole. A repeat MRI head showed regression of
the previous changes.
Four weeks into cryptococcal treatment, combined
antiretroviral therapy (cART) was initiated with Kivexa
(abacavir and lamivudine) and efavirenz. The patient then
developed a new, persistent headache and subsequent LPs
showed raised OPs, lymphocytes, and protein. Yeast cells
persisted in CSF for 3 months after starting amphotericin
and flucytosine and CSF cultures remained positive until
September 2005 (2 months after treatment start).
By October 2005, CSF cultures were negative for Cryp-
tococcus and the patient had improved clinically. VL was
undetectable and CD4 counts had risen minimally from
51 (4%) to 67 cells/𝜇L (6%). She was discharged home on
fluconazole (800mg OD), cotrimoxazole, and cART.
The patient then went on to have a difficult clinical course
with recurrent admissions over the subsequent 14 months
(Table 1).
3. Discussion
Cryptococcosis continues to be a major opportunistic
pathogen in HIV-positive patients despite global upscaling of
cART [1]. HIV causes depletion of T cell immunity allowing
infection by, most commonly, Cryptococcus neoformans (var
grubii or neoformans) [2, 3]. Cerebral cryptococcal infection
remains the commonest cause of meningitis in areas of sub-
Saharan Africa [4].
Current guidelines for therapy for cryptococcal meningi-
tis suggest amphotericin B at 0.7–1mg/kg/day (or liposomal
amphotericin B if renally impaired) combined with flucy-
tosine 100mg/kg/day switched to oral fluconazole after at
least two weeks or once CSF sterility has been achieved.
Fluconazole is then continued for a further 6 to 12 months or
until CD4 count is above 250 cells/𝜇L for 6months [1, 2, 5–10].
Predictive markers of mycological failure have been found to
be disseminated cryptococcal disease, high CSF CRAG titres
and initial treatment lacking flucytosine [2, 11].
Through immune restoration, cART has decreased mor-
bidity and mortality from AIDS-associated opportunistic
infections (OIs) [12, 13]. Although still not fully under-
stood, IRIS represents a dysregulated immune response to
pathogen-specific antigens occurring especially in HIV posi-
tive patients with advanced immunodeficiency commencing
cART [14–16]. IRIS incidence in such patients varies from
10 to 32% [17–19]. IRIS can be subdivided into either “para-
doxical” reactions which are a response to pathogen-specific
antigens despite the pathogen itself being nonviable, or
“unmasking” reactionswhich are a response to infections that
were subclinical prior to cART [14, 15, 19]. Both types of IRIS
are most common in the first 3 months after initiating cART
but paradoxical IRIS may present much later, in some cases
up to 2 years after initiation [10, 14]. Multiple manifestations
of IRIS have been reported, including mycobacterium avium
intracellulare lymphadenitis, pulmonary and neurological
tuberculosis, and cryptococcal meningitis [14, 15]. Risk fac-
tors for IRIS include disseminated OI disease; recent OI
treatment; low baseline CD4 with rapid rise after starting
cART; and high baseline HIV VL with rapid decline after
starting cART [14, 17, 20, 21].
Paradoxical IRIS inHIV-positive patients with previously
treated cryptococcal disease has been estimated between 4
and 30% and is associated with an exaggerated T-cell medi-
ated production of interferon-gamma to pathogen specific
antigens [10, 12, 18, 22, 23]. The most common presentations
of cryptococcal IRIS are either meningitis or lymphadenitis
[24]. This marked inflammatory response manifests itself
clinically, with fever, lymphadenopathy, and meningism due
to raised ICP; microbiologically, with high protein levels
and CSF white cell counts including polymorphonuclear
cells; neuroradiologically, with extensive abnormal contrast
enhancement; and histologically, with granulomas composed
mainly of macrophages (containing inert cryptococci) and
high levels of CD8+ cytotoxic lymphocytes [10, 25–28].
Our patient presented with cryptococcal meningitis as
an AIDS-defining illness. She had a low CD4 count of 51
cells/𝜇L (4%) and a high CSF CRAG titre of >1 : 25,600,
visible yeast on microscopy, and subsequent positive fungal
cultures.HerCSF remained culture positive forCryptococcus
until eight weeks after starting high-dose fluconazole, a
total of 12 weeks after presentation, indicating a massive
cryptococcal burden. Despite oral fluconazole, she had florid
recrudescence of her symptoms at 1-2months into cARTwith
focal neurology, worsening MRI changes, biopsy-proven live
Cryptococcus, and a good response to steroid therapy, typical
of an unmasking IRIS [10, 25, 29]. This initial presentation
was in keeping with the literature which highlights high
baseline fungal burden (high blood or CSF CRAG), high
fungal burden at end of amphotericin B induction treatment,
low initial CD4 count, and early initiation of ART (less
than 1-2 months from diagnosis of cryptococcal meningitis)
as risk factors for cryptococcal IRIS [30–32]. Our patient,
however, had by this time achieved only a minimal rise in her
CD4 count (51 to 67 cells/𝜇L) and, therefore, hypothetically
minimal immune reconstitution.
The AIDS Clinical Trials Group study 1564 reported
benefits for starting cART early in the context of acute OIs
(12% Cryptococcus) [33]. It is, however, our patient’s later
presentations that provide contrast to existing guidelines
for the management of cryptococcal IRIS. Eighteen months
after her initial presentation, 11 months after achieving CSF
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(a) (b)
(c)
Figure 1: (a) MRI brain 5 days into admission in August 2005 showing right-sided occipitoparietal leptomeningeal inflammation. (b) MRI
brain on readmission December 2005, 4 months after initial presentation showing worsening right-sided occipitoparietal leptomeningeal
inflammation. (c) T2-weighted MRI brain in December 2006, 16 months after initial presentation showing large clusters of ring-enhancing
lesions and leptomeningeal inflammation in the right occipitoparietal area with oedema and midline shift. Also seen but not shown on this
cross-section were smaller clustered ring-enhancing lesions in the right thalamus and left frontal and temporal lobes.
sterility, and 2 months after finishing a year’s course of
fluconazole and tapered steroids, she represented with a
new acute syndrome with significant worsening in MRI
appearance and visible budding yeast on brain biopsy (see
Figure 2), indicative of active infection. By this point, her
CD4 count had risen substantially to 437 cells/𝜇L (18%) and
this, in conjunctionwith the profound inflammatory reaction
and live budding Cryptococcus, may have indicated a relapse
of cryptococcal IRIS or disease. It appears that our patient
was unable to arrest fungal replication despite what appeared
to be a good peripheral blood CD4 count and supposed
“immune reconstitution”. This raises questions concerning
the quality of the CD4 response, compartmentalisation of
CD4 immunity, and the correlation of a rise in peripheral
CD4 count with activity of CNS immunity [34–36].
This unusual case illustrates that HIV-associated cryp-
tococcal IRIS, especially in severely immunocompromised
patients with high burden of organism, can be difficult
to distinguish from recurrent cryptococcal meningitis and
that the role of MIC in clinical practice for cryptococcal
meningitis remains to be defined [37]. Regarding MIC, our
experience with this patient does not correlate with the
recently published guidelines [38] for the management of
cryptococcal meningitis: in particular continuing flucona-
zole treatment and repeated brain biopsies were essential
for management despite the CD4 count increasing above
100 cells/𝜇L. Corticosteroids for IRIS caused substantial mor-
bidity, but there is no established alternative and possible
therapy with thalidomide would not have been safe in this
patient of childbearing potential. Were our patient to have
6 Case Reports in Neurological Medicine
(a) (b)
Figure 2: (a) Brain biopsy taken in December 2005, 4 months after initial presentation showing reactive gliosis and focally distended
perivascular spaces containing Cryptococcus. (b) Brain biopsy taken in December 2006, 16 months after initial presentation showing
encapsulated, budding yeast forms, scattered singly with some surrounding necrosis and moderate chronic inflammation. No granulomata
were seen.
continued to relapse with active cryptococcal disease, we
would have needed to consider suppressive therapy with
newer broad spectrum azoles such as voriconazole or
posaconazole (echinocandins have no activity against Cryp-
tococcus) [38].
In order to prevent relapse of symptoms, patients such
as ours may require prolongation of amphotericin B and
flucytosine induction therapy and subsequent fluconazole
and steroid maintenance therapy, beyond that recommended
by existing guidelines [39]. This case highlights the difficulty
in differentiating cryptococcal meningitis from cryptococcal
IRIS [40, 41] and emphasizes the need for further evidence
on the optimal time to start ART in HIV-positive patients
presenting with cryptococcal meningitis as highlighted by a
recent Cochrane review [41].
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